Which people with severe asthma attend pulmonary rehabilitation? Insights from the German Asthma Net
- PMID: 40470148
- PMCID: PMC12134927
- DOI: 10.1183/23120541.00689-2024
Which people with severe asthma attend pulmonary rehabilitation? Insights from the German Asthma Net
Abstract
Although its benefits have been clearly demonstrated, only 20.4% of individuals with severe asthma attended pulmonary rehabilitation (PR). PR attendees are characterised by reduced work ability and exercise capacity, and more symptoms and exacerbations. https://bit.ly/4fjzoo1.
Copyright ©The authors 2025.
Conflict of interest statement
Conflict of interest: I. Jarosch reports receiving honoraria for presentations and support received for attending conferences from CSL Behring. T. Schneeberger reports payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim; and support for attending meetings from CSL Behring. R. Gloeckl reports payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca and Sanofi. K. Milger reports consultancy fees from AstraZeneca, Chiesi and Sanofi; payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, GSK, Novartis, Chiesi and Sanofi. D. Skowasch reports support for the present study from GSK; grants from Boehringer Ingelheim, BMBF and DFG; consultancy fees from GSK, AstraZeneca, Sanofi, Janssen and MSD; payment or honoraria for lectures, presentations, manuscript writing or educational events from GSK, AstraZeneca, Sanofi, Janssen, MSD, Chiesi and Boehringer Ingelheim. C. Schulz reports consultancy fees from AstraZeneca; and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Novartis and Sanofi. S. Korn reports consultancy fees from AstraZeneca, GSK, Sanofi, Novartis and Chiesi; payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, GSK, Sanofi, Novartis, Chiesi and Berlin-Chemie; support for attending meetings from AstraZeneca, GSK and Sanofi; participation on a data safety monitoring board or advisory board with AstraZeneca, GSK, Sanofi, Novartis and Chiesi. The remaining authors have nothing to disclose.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials